After the restriction enzyme mapping of the MDV genome, we and others found an amplification of a 132 bp repeat in IRL and TRL, which caused loss of tumorgenicity of MDV. In our recent study, the loss of tumorgenicity was found to be due to the disruption of a 1.8 kb RNA gene as well as a 3.8 kb RNA gene. Exon-I is mapped to the 5'-end of the amplification and exon-II is mapped to the 3'-downstream region of the amplification. In this study we propose to further investigate the nature of the 1.8 kb RNA gene as well as the 3.8 kb RNA gene. We plan to make cDNA libraries of oncogenic and non-oncogenic MDV infected cell RNA and precisely map the 1.8 kb and 3.8 kb RNA be raising monospecific antibody to these genes. Once we determine the open reading frames of these genes and raise monospecific antibodies to these gene products, we will reconstitute oncogenic MDV by insertion of these genes back into the non-oncogenic MDV genome at the region of the TK gene or at the truncated RNA region. This will give direct evidence that these genes of MDV (1.8 kb and/or 3.8 kb RNA) are indispensable for tumor induction in chicken. Furthermore, eukaryotic expression vectors made by inserting the cDNA or the open reding frame of these genes into pZIPneo or 3'-downstream of RSV promoter will be used to determine whether H gene can transform NIH 3T3 cells or CEF. These proposed studies will further clarify the role of these genes in inducing tumors in chicken.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA031949-08A3
Application #
3170046
Study Section
Experimental Virology Study Section (EVR)
Project Start
1981-08-01
Project End
1995-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Tampa Bay Research Institute
Department
Type
DUNS #
City
Saint Petersburg
State
FL
Country
United States
Zip Code
33716
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Davidson, I; Tanaka, A; Nonoyama, M (1995) Common antigenic epitopes are present on heat-labile oligomers of MDV glycoprotein B and on HSV glycoprotein B. Virus Res 35:233-45
Peng, Q; Zeng, M; Bhuiyan, Z A et al. (1995) Isolation and characterization of Marek's disease virus (MDV) cDNAs mapping to the BamHI-I2, BamHI-Q2, and BamHI-L fragments of the MDV genome from lymphoblastoid cells transformed and persistently infected with MDV. Virology 213:590-9
Makimura, K; Peng, F Y; Tsuji, M et al. (1994) Mapping of Marek's disease virus genome: identification of junction sequences between unique and inverted repeat regions. Virus Genes 8:15-24
Peng, F; Bradley, G; Tanaka, A et al. (1992) Isolation and characterization of cDNAs from BamHI-H gene family RNAs associated with the tumorigenicity of Marek's disease virus. J Virol 66:7389-96
Nonoyama, M; Wen, L T; Tanaka, A et al. (1990) Detection of 12-o-tetradecanoylphorbol-13-acetate-induced cellular proteins that compete with the Epstein-Barr virus nuclear antigen 1 (EBNA-1) for binding to a site within the Epstein-Barr virus oriP. Adv Exp Med Biol 278:125-36
Wen, L T; Lai, P K; Bradley, G et al. (1990) Interaction of Epstein-Barr viral (EBV) origin of replication (oriP) with EBNA-1 and cellular anti-EBNA-1 proteins. Virology 178:293-6

Showing the most recent 10 out of 21 publications